Rare diseases

Larimar Therapeutics (LRMR) will host a conference call and webcast on September 29, 2025, at 8:00 am EDT to provide updates on its nomlabofusp clinical development program. The presentation will feature data from the ongoing long-term open-label study evaluating nomlabofusp for the treatment of Friedreich’s ataxia (FA). The company aims to demonstrate the drug’s long-term efficacy and safety in FA patients, addressing a significant unmet medical need. A webcast replay will be available on Larimar’s website.

Soligenix, Inc. (SNGX) announced a public offering of 5,555,560 shares of common stock (or equivalents) with warrants at $1.35 per share/warrant. The warrants are immediately exercisable at $1.35, expiring in five years. Existing warrants for 1,162,064 shares will be amended to the same price and expiration. The offering, expected to close around September 29, 2025, aims to raise $7.5 million, which will fund R&D, commercialization, and general corporate needs. A.G.P./Alliance Global Partners is the sole placement agent. This offering is under an effective SEC registration statement.

Quince Therapeutics announced a securities purchase agreement to raise approximately $11.5 million upfront, with the potential for an additional $10.4 million if warrants are exercised. The financing, priced at a premium, will fund working capital, R&D, and general corporate purposes, extending its operational runway into Q2 2026 (or potentially H2 2026). The placement is led by Nantahala Capital and is set to close in June 2025.